Research programme: cancer therapeutics - Janssen Biotech/Eureka Therapeutics
Latest Information Update: 20 Jan 2016
At a glance
- Originator Eureka Therapeutics; Janssen Biotech
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Lung cancer
Most Recent Events
- 08 Jan 2016 Early research in Lung cancer in USA (Parenteral) before January 2016
- 08 Jan 2016 Janssen Biotech and Eureka Therapeutics collaborate to develop antibody for Lung cancer